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Summary Deregulated expression of myc proto-oncogenes is implicated in several human neoplasias. We
analysed the expression of c-myc, N-myc, L-myc, max and RBI mRNAs in a panel of human gliomas and
glioma cell lines and compared the findings with normal neural cells. The max and RBI genes were included in
the study because their protein products can interact with the Myc proteins, being thus putative modulators of
Myc activity. Several gliomas contained cIL-myc mRNAs at levels higher than those in fetal brain, L-myc
predominantly in grade 11/111 and c-myc in grade III gliomas. High-level N-myc expression was detected in one
small-cell glioblastoma and lower levels in five other gliomas. In contrast, glioma cell lines totally lacked
N/L-myc expression. The in situ hybridisations revealed mutually exclusive topographic distribution of myc
and glial fibrillary acidic protein (GFAP) mRNAs, and a lack of correlation between myc expression and
proliferative activity. max and RBI mRNAs were detected in most tumours and cell lines. The glioma cells
displayed interesting alternative splicing patterns of max mRNAs encoding Max proteins which either suppress
(Max) or augment (AMax) the transforming activity of Myc. We conclude that (1) glioma cells in vivo may
coexpress several myc genes, thus resembling fetal neural cells; but (2) cultured glioma cells expression only
c-myc; (3) myc, max and RBI are regulated independently in glioma cells; and (4) alternative processing of
max mRNA in some glioma cells results in AMax encoding mRNAs not seen in normal fetal brain.
Proto-oncogenes relay signals that regulate cell growth and
differentiation, and their aberrant activation is implicated in
a wide spectrum of neoplasia. The human myc proto-onco-
genes (c-myc, N-myc and L-myc) encode related DNA-binding
phosphoproteins that presumably function as transcriptional
regulators of specific target genes (Luscher & Eisenman,
1990). The Myc proteins can bind DNA alone, but more
effectively in a complex with Max, a heterodimeric Myc
DNA-binding partner (Blackwood & Eisenman, 1991). Max
contains a DNA-binding basic region (b) N-terminal to
helix-loop-helix (HLH) and leucine zipper (Zip) dimerisa-
tion motifs. Dimerisation with Max increases the capability
of Myc to bind DNA in a sequence-specific manner (Black-
wood & Eisenman, 1991), and modulates the transforming
activity of Myc (Prendergast et al., 1991). Max associates
with N-Myc in vivo in neuroblastoma cells (Wenzel et al.,
1991), and with c-Myc, N-Myc as well as L-Myc in rat
embryo fibroblasts (Mukherjee et al., 1992). This interaction
appears to be a common mechanism through which Myc
function is mediated (Mukherjee et al., 1992). Several differ-
ent forms of Max are generated through alternative mRNA
splicing: Max suppresses, while the C-terminally truncated
AMax enhances, Myc transformation (Makela et al., 1992;
Vastrik et al., 1993). These opposing effects of Max and
AMax on the transforming activity of Myc suggest that max
mRNA processing may be an important mechanism to mod-
ulate Myc activity. Intriguingly, the N-termini of c-Myc and
N-Myc bind to the retinoblastoma (RB1) protein in vitro
(Rustgi et al., 1991). Inactivation of the RB1 gene is strongly
implicated in the pathogenesis of childhood retinoblastomas
and in sporadic tumours of other cell lineages as well (Gallie
et al., 1990). The RB1 protein may thus, in addition to Max,
be a modulator of Myc activity, although the interaction has
not been demonstrated in vivo.
High-level myc expression releases several cell types from
growth-regulatory constraints, e.g. by reducing their growth
factor requirements for continuous proliferation and by caus-
ing a dedifferentiation to a more primitive phenotype, thereby
contributing to a neoplastic phenotype (Luscher & Eisenman,
1990; DePinho et al., 1991). Genomic amplifications of N-
myc or L-myc and consequent high-level mRNA and protein
expression are frequent in tumours displaying neuroectoder-
mal characteristics, particularly in neuroblastomas (N-myc)
(Kohl et al., 1984; Schwab et al., 1984) and small-cell lung
carcinomas (SCLC) (N/L-myc) (Nau et al., 1985, 1986; Wong
et al., 1986; Johnson et al., 1988). c-myc amplifications are
also frequent in several other tumour types (Alitalo et al.,
1987).
The genetic events involved in CNS tumorigenesis have
recently been reviewed (James & Collins, 1992). Among the
best-characterised alterations is the frequent amplification
and overexpression of the EGF receptor gene (Libermann et
al., 1985), but sporadically amplified c-myc (Trent et al.,
1986), N-myc (Bigner et al., 1988; Fujimoto et al., 1989) and
c-myb (Welter et al., 1990) genes have also been described in
glioma cells.
We have previously characterised the developmental ex-
pression of the three myc genes and the alternative mRNA
processing of L-myc in fetal brain (Hirvonen et al., 1990). We
found that L-myc, N-myc as well as c-myc expression is not
coupled to mitotic activity in fetal brain, suggesting that myc
expression is characteristic for an immature phenotype rather
than cell proliferation. Bearing in mind that malignant
tumours often overexpress the same proto-oncogenes that are
active during the normal embryonic development and growth
of the cells of origin of the tumour, we have now extended
these analyses to human central nervous system (CNS) malig-
nancies, in order to compare the expression of myc genes in
malignant and normal neuroepithelial cell growth. We now
report differentially regulated (co)expression of the myc genes
(c-, N- and L-myc), and the max and RBI genes (encoding
putative modulators of Myc activity), in a panel of human
brain tumours and glioma cell lines, using Northern hyb-
ridisation, RNAase protection and, in selected cases, in situ
hybridisation. The findings are compared with normal fetal
brain as well as with the expression of well-established
neuronal and glial marker genes: mid-weight neurofilament
subunit (NF-M) specific for neurons, and glial fibrillary
acidic protein (GFAP) and vimentin, which within the CNS
is specific for glial cells,
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Materials and methods
Brain tumour specimens
Primary brain tumour samples (n = 13) were obtained at
neurosurgical operations. The normal adult white and grey
matter specimens were obtained from a patient operated on
for an arteriovenous malformation, with no disorder affecting
the white or grey matter. Human fetal brain specimens were
obtained from therapeutic second-trimester abortuses as de-
scribed previously, with approval of the ethical committee of
Turku University Central Hospital (Hirvonen et al., 1990).
These were chosen as controls because they represent the
normal counterparts of the tumour cells, albeit they consist
of heterogeneous cell populations. The tissue pieces were
divided into three specimens: one of two adjacent samples
was snap-frozen in liquid nitrogen immediately upon removal
for the isolation of RNA and DNA, while the other was sent
to the Department of Pathology for diagnostic frozen sec-
tion. The third part of the samples was fixed in phosphate-
buffered 4% formaldehyde and processed to routine paraffin
specimens to be used in the final diagnostics and in situ
hybridisation analyses. The tumours were classified according
to the WHO International Histological Classification of
Tumors No. 21 (Zuilch, 1979). The grading of astrocytomas
and glioblastomas that was used corresponds closely to that
of the St Anne-Mayo system (Daumas-Duport et al., 1988),
i.e. grade I, no or minimal cellular atypia and low cell
density; grade II, some cellular atypia and higher cell density;
grade III, cellular atypia, mitoses, vascular proliferation;
glioblastoma, marked atypia, mitoses, necroses. The diagnosis
of small-cell glioblastoma (SCGB) was ascribed to a tumour,
which first presented as a grade III astrocytoma and upon
recurrence 1 year later (analysed in this study) disclosed a
microscopic picture dominated by tightly packed small,
actively dividing cells with intervening anaplastic astrocytic
cells. A summary of the tumours is given in Table I.
Glioma cell lines
The human glioma cell lines U-118 MG, U-251 MG, U-343,
U-410, U-251 MG-Sp, U-178 MG and U-1242 MG were a
kind gift from B. Westermark, Uppsala, Sweden. The glioma
lines A-172, T98G, U-87 MG, U-138 MG, U-373 MG, Hs
683 and the neuroglioma line H4 were obtained through the
ATCC. The cells were cultured in Dulbecco's modified mini-
mal essential medium (DMEM) supplemented with 10%
heat-inactivated fetal calf serum and antibiotics.
Isolation and analysis ofRNA
Total cellular RNAs were isolated as previously described
(Chirgwin et al., 1979). The tumour specimens were homo-
genised in 4 M guanidinium isothiocyanate (GIT) and the
RNAs purified by ultracentrifugation through 5.7 M caesium
chloride cushions. From the glioma cell lines total RNA was
isolated by lysing confluent cultures directly into GIT; fresh
medium was added to the cultures 24 h prior to RNA isola-
tion, and the cells were washed twice with ice-cold phos-
phate-buffered saline (PBS) before the GIT lysis. Aliquots of
15 jig total cellular RNAs were size fractionated in 1%
agarose/formaldehyde gels, blotted onto nylon membrane
(GeneScreen Plus, DuPont, NEN, MA, USA), and hybrid-
ised under stringent conditions according to the manufac-
turer's suggestions. The sequential probing of the filters was
carried out with intervening removal of the previous probe as
suggested by the manufacturer.
Probes
A description of the cRNA template clones pC3bs3l6 (c-
myc), pN2bs349 (N-myc) and pRb322 (RBJ) has been pub-
lished previously (Hirvonen et al., 1991). Primary screening
of L-myc expression was carried out by RNAase protections
using cRNA generated from genomic clone pL2GEM450
(Saksela et al., 1989) by SP6 polymerase. For further
analyses of L-myc mRNA structure, the cRNA template
clone pU313.blue was used (Hirvonen et al., 1991). It allows
simultaneous analysis of all known processing variants of
L-myc mRNA. The cDNA clone HELmax (MIkela et al.,
1992) was used for the analysis of max mRNA. The human
GFAP cDNA clone pGF181-5 (Nishiyama et al., 1989) was a
kind gift from T. Kumanishi. The cDNA clones cHuVim
(Perreau et al., 1988) and pNF1.2 (Myers et al., 1987) for
human vimentin and the mid-weight neurofilament subunit,
respectively, were obtained through the ATCC. In the in situ
hybridisations, the L-myc probe was a HindIII-EcoRI frag-
ment of L-myc exon III, because L-myc mRNAs in the brain
tumours analysed contained exon III. The N-myc probe in
the in situ hybridisations was a 1.l-kbp RsaI-AccI fragment
containing 32 bp of exon II and 1034 bp of exon III.
For filter hybridisations, the specific fragments were iso-
Table I Summary of mRNA analyses in the astrocytoma samples
Specimen PAD/grade c-myc N-myc L-myc max RBJ GFAP VIM NF-M
Normal adult cortex - (+) (-) - + (-) - +
Normal adult white matter - - (-) - + + +
Fetal brain + + + + + + + - + + +
No. 1 ACI + - + + + + + +
No.2 ACT - + - + + + - +
No.3 GN + - + + ++ ++ +++ +
No. 4 AC II +a a + + + + + + + + + +
No. 5 AC II + + + - + + - -
No. 6 AC II ND ND + + ND ND ND ND ND
No.7 ACIII ++a -a + + + ++ ++ +
No. 8 ACIII + + + + + + - + + + -
No.9 ACIII + + + + ++ ++ ++ -
No. 10 GB + + + + + + + + + + + +++ -
No. 11 GB ++ - - - + + + + -
No. 12 GB -a _a _ + + + + -
No. 13 SCGB + +a + + +a + + + + + - + + +
No. 14 NB IV _ a + + + +a - + + - + + +
No. 15 NB IVS + + + + + + + + - + -
No. 16 SCLC + + + - + + + + + - + -
No. 17 CNS lymphoma + + - - + + - + +
The following symbols denote the mRNA levels in an increasing order: -, +, + +, +++, ++++. Ofthe
glioblastomas, nos. 11 and 12 are ofthe classic type with pseudopalisadic necroses, while no. 13 is the PNET-like
small-cell glioblastoma (SCGB). amyc analyses carried out by Northern hybridisation only, not by RNAase
protection, owing topaucity ofRNA. Abbreviations: GFAP, glial fibrillary acidicprotein; VIM,vimentin; NF-M,
mid-weight neurofilament subunit; AC, astrocytoma; GN, ganglioglioma; GB, glioblastoma; SCGB, small-cell
glioblastoma; NB, neuroblastoma; SCLC, small-cell lung carcinoma (CNS metastasis).18 H.E. HIRVONEN et al.
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Figure 1 Northern hybridization analyses of c-myc, N-myc, max, neurofilament-M (NF-M), vimentin (Vim) and GFAP mRNAs
in human CNS tumours. For controls, RNAs from normal fetal brain and normal adult grey (GM) and white (WM) matter were
included. The sizes of the transcripts are indicated on the right. Ethidium bromide (EtBr)-stained RNAs are shown below, with the
28S and 18S rRNAs marked.
lated and purified from agarose gels by isotachophoresis
(Ofverstedt et al., 1984), and labelled by the random-priming
method (Feinberg & Vogelstein, 1983) with [(-32P]dCTP
(Amersham, UK) to specific activities of 1-2 x 109c.p.m.
,ug 1. The unincorporated nucleotides were removed in
Sephadex G50 spin columns.
RNAase protection assays
For RNAase protection assays, the cRNA probes were
generated from linearised templates (see above) using com-
mercial transcription kits (Transprobe SP and T, Pharmacia,
Sweden) with [a-32P]UTP (Amersham, UK). In some experi-
ments, the L-myc (pL2Gem450) and RBI probes were com-
bined in order to use the RBI signal as an internal control.
The N-myc and c-myc cRNA probes (protected as 353- and
316-nt fragments respectively) were not mixed with the RBI
probe to avoid possible blurring of the myc signals by an
eventual residual RBI probe (322 nt) observed in some
experiments. Synthesis and purification of the probes and the
hybridisations were carried out as described previously (Hir-
vonen et al., 1990).myc AND max EXPRESSION IN GLIOMAS 19
x
co L. t
Iu~~~~~- t~
O o a: C-
t- 12-..Ln ooC
r. - LD MZ L
r
(373 nt)
' o0
SD x
v it r~~~
oJo o SXO - ~~~~~(J
lE0 DE
t & ~ ~ - aN~~~ 2~~~~N
(419 nt)
c-myc N-myc
Figure 2 RNAase protection analysis of myc mRNAs in human malignant gliomas and fetal brain. The sizes of the cRNA probes
are shown to the left of each panel. The sizes of the protected fragments are 316 nt (c-myc), 353 nt (N-myc) and 421 and 457 nt
(L-myc). The two L-myc fragments (421 and 457 nt) are protected by alternatively spliced L-myc transcripts. Analysis of N-myc
mRNA was carried out to verify the weak in situ hybridisation signals (see Figure 5) obtained in some tumours which in Northem
hybridisation lacked detectable N-myc mRNA (see Figure 1). The 419-nt band in the N-myc panel results from residual
incompletely digested probe.
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Figure 3 RNAase protection analysis of myc and RBI mRNAs in glioma cell lines. c-myc and RBI but not N-myc or L-myc
probes are protected by glioma cell RNAs. The fetal brain RNA used as positive control (the rightmost lane) is slightly degraded.
Therefore this RNA yields a relatively stronger signal in the RNAase protection than in the Northern analysis (cf. Figure 1).
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In situ hybridisations
The in situ hybridisations were carried out on 5-+m-thick
sections of formaldehyde-fixed, paraffin-embedded material
with [x-35S]dATP-labelled probes (Sandberg & Vuorio, 1987).
As a negative control probe we used bacteriophage l DNA
fragments of 100-790 bp generated with BglI. After stringent
washes the dried slides were dipped into autoradiography
emulsion (Kodak, NTB 3), exposed for 3-12 weeks, develop-
ed and counterstained with haematoxylin.
Results
myc and max mRNA expression in brain tumours
Northern hybridisations revealed c-myc expression at levels
higher than in adult brain in 10 out of 13 surgically removed
gliomas. The c-myc signal intensities were stronger in the
high-grade (III and IV) and weaker in the low-grade gliomas.
However, one grade IV and one grade I tumour lacked c-myc
signals. Enhanced N-myc expression was detected by North-
ern hybridisation in only one tumour, a highly malignant
small-cell glioblastoma (SCGB), in addition to the stage IV
neuroblastoma used as a positive N-myc control (Figure 1).
The N-myc copy number in this tumour appeared normal as
analysed by Southern hybridisation (not shown). However,
the in situ hybridisations revealed N-myc-reactive cells in
some other gliomas after long exposure times (see below).
This finding was verified by the more sensitive RNAase
protection analyses, which indeed revealed definite N-myc
signals in five gliomas (Figure 2). These signals were several-
fold stronger than the very weak signal observed in the adult
brain RNA.
Elevated L-myc mRNA levels (compared with fetal brain)
were detected in 5 out of 13 tumours (Figure 2). The highest
L-myc mRNA levels were observed in the grade II/III astro-
cytomas and the SCGB. The two protected L-myc fragments
(421 and 457 nt) indicated that at least two L-myc mRNA
forms (either lacking or retaining intron I) were present.
Further RNAase protection analyses revealed that the major-
ity of L-myc transcripts contained exon III (data not shown-).
Thus, only the two long L-myc mRNA splice variants (3.6 kb
and 3.8 kb) were present, but not the short transcripts which
lack exon III and which have been detected in SCLC cell
lines and some leukaemia cells only (Kaye et al., 1988;
Hirvonen et al., 1991). The RBI mRNA, which is expressed
at almost uniform levels in normal cells and tissues, was
detectable in all tumours as well as in fetal and adult brain
(shown for glioma cell lines in Figure 3).
Hybridisation with the max probe yielded signals in 9 out
of 13 glioma tumours. The overall expression patterns of
max did not parallel those of c-myc, N-myc or L-myc (Figure
1). Five different max mRNAs have been identified, with
sizes of 1.9 kb, 2.3 kb, 2.4 kb, 3.0 kb and 3.5 kb. The major
2.3-kb and 2.4-kb mRNAs encode for Max and AMax
respectively (Vastrik et al., 1993). In some tumours, addi-
tional bands of 1.9 kb, 3.0 kb and 3.5 kb were observed. The
3.0-kb mRNA codes for AMax, and the 3.5-kb mRNA for a
AMax-related polypeptide, which lack the nuclear targeting
signal (Viistrik et al., 1993). The 1.9-kb and 2.3-kb mRNAs
encode 'normal' Max (Blackwood & Eisenman, 1991). These
max mRNA processing patterns differed from those seen in
normal fetal brain (see Figures 1 and 4 and Table II).
Probes for cell type-specific intermediate filament mRNAs
were analysed to confirm and further characterise the histo-
pathological classification of the tumours and glioma cell
lines. Vimentin mRNA was detected in all tumours and cell
lines, as well as in fetal but not in adult brain. GFAP mRNA
was present in most tumours but in only four glioma cell
lines. Normal adult brain white matter gave a GFAP signal,
while fetal brain and normal adult grey matter yielded only
faint signals after very long exposure times (not visible in
Figure 1). The mid-weight neurofilament subunit (NF-M)
mRNA was expressed in adult grey matter, fetal brain and in
some low-grade gliomas, but not in adult white matter. In
addition, NF-M mRNA was detected in the grade IV neuro-
blastoma and in the SCGB tumour. The one primary CNS
lymphoma and the SCLC brain metastasis lacked GFAP and
NF-M mRNAs, consistent with their non-glial and non-
neural origin (Table I).
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Figure 4 Differential expression of c-myc and max in glioma cell
lines. The c-myc and max signals result from sequential hybri-
disation of the same filter, while vimentin (Vim) and GFAP
hybridisations were carried out in parallel on an identical dup-
licate filter. Note that the levels of myc and max transcripts do
not parallel each other. The lowermost panel shows ethidium
bromide-stained RNAs, with the 28S and 18S rRNAs marked.
The glioma lines lack entirely N-myc and L-myc mRNAs (see
Figure 3). U-87 MG(f) is RNA extracted from U-87 MG cell
spheroids spontaneously shed into the culture medium.
Table II Alternative splicing of max mRNAs in glioma cells
Max mRNA size (encoded polypeptide)
1.9kb 2.3kb (Max 3.0kb 3.5kb
Cell line (Max) and AMax) (AMax) (AMaxa)
A-172 + + - -
T98G - - - +
U-87MG - ++ + +
U-87 MG(f) - + + +
U-138 MG + ++ - -
U-373 MG + ++ - -
Hs683 - (+) + +
H4 - + - (+)
U-118MG - + - -
U-251 MG - + - (+)
U-251MG-Sp + ++ - -
U-343 MG + ++ - -
U-410 MG - + - -
U-178 MG - ++ - +
U-1242 MG + +++ - (+)
Fetal brain (+) + -
The following symbols denote semiquantitation of the levels of the
different max mRNA forms, in increasing order: -, +, + +, +++.
The 2.3-kb and 2.4-kb mRNAs encoding Max and AMax, respectively,
migrate very closely therefore they are listed together in the table as the
2.3-kb column. aThe 3.5-kb transcript encodes a variant AMax protein
(Vastrik et al., 1993).myc AND max EXPRESSION IN GLIOMAS 21
Table III Summary ofmRNA analyses in the gliomas cell lines
Cell line c-myc N-myc L-myc max RBI GFAP VIM NF-M
A-172 ++ - - + ++ - +++ -
T98G ++++ - - (+) + - ++ -
U-87 MG ++++ - - ++ + - ++++ -
U-87 MG(f) +++ - - + + - +++ -
U-138 MG + + + - - + + + + + - + + + -
U-373 MG + - - + + + ++ ++ + +++ -
Hs 683 + - - + + + - ++ -
H4 + + - - + + - + -
U-118 MG +++ - - + ++ - +++ -
U-251 MG + + - - + + + + + + + + -
U-251 MG-Sp + + - - + + ++ ++ + ++++ -
U-343 MG ++ - - ++ + +- -
U-410MG + - - + + - ++++ -
U-178 MG + - - + + + + + -
U-1242 MG + + - - + + +-+ -
Fetal brain + + + + + + + - + + +
The following symbols denote semiquantitation of the mRNA levels in increasing order:-, +, + +,
+ + +, + + + +. N/L-myc and RBI mRNAs were analysed by RNAase protection only, c-myc by
Northern hybridisation and RNAase protection, and vimentin, GFAP and NF-M by Northernhybridisa-
tion only. For max, the semiquantitation given indicates presence of some of the several max mRNAs
generatedviaalternative splicing; thesearelistedseparatelyindetailinTaleII. U-87MG(f) = U-87MGcell
spheroids shed into the culture medium.
Expression ofmyc, max and RB1 mRNAs in glioma cell lines
In the glioma cell lines, the N-myc, L-myc and RBI mRNAs
were analysed by RNAase protection only, while max, neuro-
filament-M, GFAP and vimentin mRNA expression analyses
were carried out by Northern hybridisations. Non-coordinate
expression patterns of c-myc and max were evident in the cell
lines. For example, T98G cells yielded a very strong c-myc
signal but almost entirely lacked max mRNA except a very
weak 3.5-kb band, corresponding to a variant AMax (Viistrik
et al., 1993), U-373 MG cells showed strong max signals but
only a weak c-myc signal, while U-1242 cells contained both
intense max and c-myc signals (Figure 4). All the glioma cell
lines lacked entirely N-myc and L-myc mRNAs as analysed
by RNAase protection (Figure 3). The strong c-myc signal
observed in fetal brain in these protection analyses (Figure 3,
rightmost lane) contrasts with the relatively weaker c-myc
signal obtained in Northern analysis of the same specimen
(Figure 3, rightmost lane). This is due to partial degradation of
this particular RNA sample, which results in the dispro-
portionally weaker Northern signal in Figure 4. However, the
316-nt c-myc cRNA probe can be efficiently protected even
by the partially degraded c-myc mRNA. With the exception
of the H4 neuroglioma cell lines, all the cell lines yielded
strong vimentin signals, while GFAP mRNA was detectable
only in U-373, U-251 MG, U-251 MG-Sp and U-178 MG
cells. None of the cell lines contained NF-M mRNA as
analysed by Northern hybridisation. These expression data
are summarised in Table III. As in the tumours, max mRNA
processing patterns exhibited cell line-specific variation, re-
sulting in the production of Max and AMax-encoding
mRNAs at varying proportions. Data on these alternative
max mRNA splice variants are summarised in Table II.
Localisation ofmyc and GFAP mRNAs by in situ
hybridisation
In selected gliomas, in situ hybridisation was utilised to
localise and identify cells expressing myc and GFAP genes.
Great topographic variation was observed in the myc hybri-
disation signal intensities. The myc autoradiographic grains
were localised over malignant cells, but the strongest signals
did not co-localise with regions of the highest mitotic
activity. The glioblastoma with the highest c-myc mRNA
levels (no. 10) displayed accentuated c-myc signals over some
but not all malignant cell clusters, and in particular over
pseudopalisadic tumour cell formations surrounding the
necrotic lesion. In contrast, the reactive endothelial cell pro-
liferations lacked a c-myc signal (Figure 5a-d). A few glioma
cells also reacted with the N-myc probe, but the signal inten-
sities were much weaker than with the c-myc probe. This
weak N-myc signal was further confirmed by RNAase pro-
tections (see above: compare Figures 1 and 2). We observed
an inverse topographic localisation of the GFAP and c-myc
hybridisation signals: the cells with the highest c-myc expres-
sion showed only a weak or no GFAP signal (compare
Figure 5b and d), while strongly GFAP-positive cells lacked
c-myc mRNA (compare Figure Sf and h).
The SCGB tumour (no. 13) which had very high N-myc
mRNA levels, displayed a non-identical topographic distribu-
tion of N-myc, L-myc and c-myc mRNA signals. The tumour
cells displayed heterogeneous N-myc signal with some very
intensely labelled tumour cell clusters, which lacked c/L-myc
RNA (Figure 6a-e). In contrast, within areas with the
highest proliferative activity only scattered cells contained
N-myc mRNA. Areas containing reactive astrocytes mixed
among malignant cells yielded positive hybridisation signals
with c-myc, N-myc and L-myc probes, but not with entirely
similar distribution patterns (Figure 6f-j). Thus, subpopula-
tions of cells with differentially activated myc expression exist
within this rare tumour.
Discussion
Several glioma tumours contained N-myc and L-myc mRNAs
as detected by RNAase protection, in addition to the high
c-myc mRNA levels present in most glioma tumours and cell
lines. Some tumours and most cell lines exhibited strong max
mRNA signals, with evidence of differential alternative splic-
ing. RBI mRNA was detected in all the gliomas, suggesting
that RBI deletions play no role in glial cell transformation.
However, subtle mutations abolishing the production of a
normal RBI protein cannot be detected by the methods used.
Vimentin mRNA was detectable in all the tumours and cell
lines, GFAP in most glioma tumours but in only four glioma
cell lines. NF-M mRNA was absent from the cell lines and
present in only a few low-grade gliomas, the signals most
probably originating from neurons within the tumour tissue.
No definite clinical characteristics could be assigned to
different myc or max expression profiles in this limited set of
patients. However, the higher c-myc mRNA levels and simul-
taneous presence of N-myc and L-myc mRNAs paralleled a
higher grade of malignancy in astrocytomas grade I-III,
whereas in the grade IV classic glioblastomas N-myc and
L-myc were not active. The enhanced myc expression prob-
ably results from increased transcription or prolonged22 H.E. HIRVONEN et al.
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Figure 5 In situ hybridisation analysis ofc-myc, N-myc and GFAP mRNA. a-d and e-h, respectively, represent the same fields of
serial sections of a glioblastoma (tumour no. 10) hybridised with the different probes. a-d, A strong c-myc signal is seen in b over
malignant cells surrounding the necrotic area (n) and the endothelial cell proliferation (en), while most c-myc-positive cells remain
GFAP negative (d). Some c-myc-reactive cells also yield a weak N-myc signal (c). This N-myc signal was verified by RNAase
protection analyses (Figure 2), although in Northern hybridisation this tumour appeared devoid of N-myc mRNA. e-h, An
opposite topographic distribution is evident for the c-myc vs GFAP signals. The reactive astrocytes in this field show a very strong
GFAP signal (h), only an extremely weak c-myc signal (f), and no N-myc signal (g). Bar = 100gm.
mRNA half-life, since we did not detect amplified myc genes
in our tumour panel as analysed by Southern hybridisation.
Enhanced expression of the N-myc gene has been implicat-
ed in the pathogenesis of extracranial tumours with neuro-
ectodermal characteristics, such as peripheral neuroblastomas
and some cases of SCLC (DePinho et al., 1991). In neuro-
blastomas, N-myc amplification is a strong indicator of poor
prognosis, independently of other staging criteria (Brodeur et
al., 1984; Seeger et al., 1985). Our results show that some
glioma tumours may express N-myc mRNA simultaneously
with c-myc and/or L-myc. The N-myc mRNA levels in these
tumours are detectable by RNAase protection but not by
Northern hybridisation. The partially overlapping but non-
identical topographic distribution patterns of the myc in situ
hybridisation signals are suggestive of differential regulation
of the genes in glial cells. The high levels of N-myc in the
SCGB differed sharply from other high-grade gliomas. The
histopathological picture of this tumour was dominated by
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Figure 6 Differential localisation of myc mRNAs in the small-cell glioblastoma tumour (SCGB). b, A strong N-myc signal in
tumour cells that lack c-myc (c), L-myc (d) and GFAP (e) mRNAs. a, A bright-field image of the same field shown in b-e. f-j,
Tumour cells mixed among few reactive astrocytes show scattered, but not strictly identical distribution, patterns of c-myc (h),
N-myc (g) and L-myc (i) mRNAs, but lack of GFAP mRNA (). Bar in a (for a-e) and f (for f-j) = 200gm.
undifferentiated small cells identical to those characteristic of
primitive neuroecotodermal tumours (PNETs). This, together
with the presence of NF-M and vimentin mRNA and the
lack of GFAP mRNA, makes it difficult to assign a specific
diagnosis for this tumour. The diagnosis of PNET with
neuronal and glial differentiation would be justified for this
rare tumour, but since PNET terminology is somewhat cont-
roversial the diagnosis of SCGB has been adhered to here.24 H.E. HIRVONEN et al.
The finding prompts further investigations as to whether
high-level N-myc expression could be a useful marker for
malignant small-cell tumours in the brain, i.e. for the dis-
puted PNET group (Rorke, 1983), particularly if comp-
lemented with other cell type-specific markers of tumour
differentiation and stage.
L-myc expression has not been previously reported in
gliomas. In our tumour material, several gliomas contained
L-myc mRNAs at levels equal to or in excess of those in fetal
brain. This underlines the usefulness of sensitive RNAase
protection analyses rather than ordinary Northern hybridisa-
tion in studies of low-abundancy mRNAs like L-myc. Even
though L-myc (and N-myc) mRNAs were present in most
grade III malignant astrocytomas, they were absent from two
classic glioblastomas. In contrast, the glioma cell lines
adapted to growth in vitro lacked L-myc and N-myc mRNAs,
but most of them contained high-levels of c-myc mRNA.
This finding is consistent with earlier observations of a lack
of N-myc and L-myc mRNAs and presence of c-myc mRNA
in glioma cell lines (LaRocca et al., 1989).
In situ hybridisations revealed the highest myc mRNA
levels in regions distinct from those with the highest pro-
liferative activity. This finding parallels our observations and
those of others of uncoupling of N-myc (Grady et al., 1987;
Hirvonen et al., 1989) as well as c-myc and L-myc (Hirvonen
et al., 1990) expression from mitotic activity in fetal brain. In
gliomas, the high myc mRNA levels may be linked to a
dedifferentiated state rather than proliferative activity, as is
the case in developing fetal CNS. This notion is supported by
the finding that GFAP and c-myc mRNAs display mutually
exclusive topographic distribution patterns in gliomas as
analysed by in situ hybridisation. Similarly, the glioma cell
lines with the highest c-myc expression levels were negative
for GFAP mRNA but did contain vimentin mRNA, which is
the earlier of the two intermediate filaments expressed during
glial cell differentiation.
Several glioma cells and tumours contained max mRNA at
levels equal to or in excess of those found in normal human
fetal brain. max mRNA levels in glioma cells are regulated
independently of the myc genes, and show great variation
between different cell lines. Interestingly, the max mRNA
processing patterns varied between different glioma tumours
and glioma lines. This may be offunctional importance, since
alternative max mRNA processing results in at least five
different mRNA forms with different protein-coding capacit-
ies and opposing effects on the transforming activity of Myc.
The first identified, Max (Blackwood & Eisenman, 1991),
suppresses while the C-terminally truncated AMax augments
Myc transformation (Miikela et al., 1992). In addition to the
major 2.3- and 2.4-kb bands representing Max- and AMax-
encoding mRNAs, respectively, several glioma cells contained
additional max mRNAs of 1.9 kb, 3.0 kb and 3.5 kb. Recent
data indicate that the 3.0-kb and 3.5-kb max mRNAs encode
Max polypeptides that are structurally identical (3.0 kb) or
highly similar (3.5 kb) to AMax, and which enhance the
transforming activity of Myc in Myc-Ras co-transformation
assays (Viistrik et al., 1993). The amount and composition of
the different Myc-Max heterodimers may thus be regulated
via max transcription and mRNA splicing, in addition to the
regulation ofmyc mRNA levels. In K562 cells, a pH decrease
causes a switch from the 2.3- and 2.4-kb max mRNAs to the
3.5-kb mRNA form, suggesting that acidification of the cul-
ture medium may regulate max mRNA processing (Vastrik et
al., 1993). In the case of the glioma cells analysed here we
consider this an unlikely source of max mRNA splice pattern
variation between different cell lines, as all the cultures were
confluent and medium was changed 24 h prior to RNA
extraction. Further studies will undoubtedly clarify the func-
tional significance of the different Max forms in normal and
malignant neuroectodermal cells and their derivatives.
We have previously reported combinatorial expression of
several myc genes in human leukaemias and leukaemia cell
lines (Hirvonen et al., 1991). Our present results suggest that
some gliomas may coexpress several myc genes, thus in part
augmenting the restricted tissue spectrum of N-myc and L-
myc expression. It is possible that L-myc and N-myc are
transiently activated in some early stages of the transforma-
tion of glial cells and contribute to their escape from their
growth restraints. In this context it is interesting that sus-
tained N-myc expression in neuroblastoma cells maintains
their phenotypic instability manifested as a transdifferent-
iation potential, which can be abolished by blocking N-Myc
production using antisense N-myc expression constructs
(Whitesell et al., 1991). The discrepancy between L-myc and
N-myc expression in gliomas in vivo as opposed to glioma
cells in vitro does not result from eventual normal cells
trapped within the biopsy specimens, as in the in situ analyses
the L-myc and N-myc signals were located over neoplastic
glial cells. It is possible that culture conditions select for the
glioma cells with the highest c-myc expression levels, which
conceivably would result in a cell population with silent
N-myc and L-myc genes, as a result of negative myc cross-
regulation. Since c-myc but not N- or L-myc appears to be
involved in the signalling pathways of several growth factors,
c-myc expression might best allow the glioma cells to circum-
vent the lack of exogenous growth factors in culture. Further
analysis of myc and max in normal CNS cells and identi-
fication of their target genes in glioma cells will undoubtedly
be helpful in establishing their roles in normal and malignant
glial cell growth.
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